cabotegravir

an HIV integrase strand transfer inhibitor

Also Known As:

(3S,11aR)-N-((2,6-difluoropyridin-3-yl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; Apretude; GSK-1265744; GSK-1265744A; GSK-1265744B; GSK1265744; GSK1265744A; GSK1265744B; GSK744; N-((2,4-difluorophenyl)methyl)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro(1,3)oxazolo(3,2-a)pyrido(1,2-d)pyrazine-8-carboxamide; S-265744; S-265744B; Vocabria; cabotegravir extended-release injectable suspension; cabotegravir sodium; sodium (3S,11aR)-8-(((2,4-difluorophenyl)methyl)carbamoyl)-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydrooxazolo(3,2-a)pyrido(1,2-d)pyrazin-6-olate

Networked: 97 relevant articles (7 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Pyridones: 14
      - cabotegravir: 97
  - Piperazines: 26
    - Diketopiperazines: 59
      - cabotegravir: 97

Experts

1.	Spreen, William R: 15 articles (01/2022 - 03/2014)
2.	Margolis, David A: 12 articles (12/2021 - 07/2015)
3.	Ford, Susan L: 12 articles (11/2021 - 07/2015)
4.	Smith, Kimberly Y: 10 articles (12/2021 - 10/2015)
5.	Patel, Parul: 9 articles (12/2021 - 01/2017)
6.	Crauwels, Herta: 6 articles (12/2021 - 09/2017)
7.	Spreen, William: 6 articles (12/2021 - 01/2015)
8.	Markowitz, Martin: 6 articles (04/2018 - 03/2014)
9.	Adeyeye, Adeola: 5 articles (01/2022 - 01/2020)
10.	Cohen, Myron S: 5 articles (01/2022 - 01/2020)

Related Diseases

1.	Infections 04/01/2018 - "Areas covered: Here, we review trials of cabotegravir (CAB) as treatment of HIV-1 infection and its potential use as pre-exposure prophylaxis (PrEP) in high risk individuals, including issues around oral lead in and potential resistance emergence. " 12/01/2023 - "Infection within 6 months of cabotegravir exposure was associated with diagnostic delays and INSTI resistance. " 01/01/2023 - "Breakthrough HIV-1 infection in setting of cabotegravir for HIV pre-exposure prophylaxis." 01/01/2023 - "Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection." 01/01/2019 - "Drug resistance emergence in macaques administered cabotegravir long-acting for pre-exposure prophylaxis during acute SHIV infection."
2.	HIV Infections (HIV Infection) 07/01/2023 - "Due to the long dosing interval (8 weeks), long-acting cabotegravir has low compliance requirements for people at high risk of HIV infection. " 01/19/2023 - "As most new medications, Cabotegravir (CAB) was recently approved as an antiretroviral treatment of HIV infection without in-depth safety information on in utero exposure. " 01/01/2023 - "For cabotegravir to have a significant impact on HIV infections, millions will need to be treated at affordable prices in a wide range of countries." 01/01/2022 - "Cabotegravir sodium (CAB-Na) is a poorly soluble anti- human immunodeficiency virus (HIV) drug for the treatment and pre-exposure prophylaxis of HIV infection that lends itself to depot formation following intradermal delivery but presents significant challenges when delivered via HF-MAPs, whose nature is aqueous. " 03/01/2021 - " opinion: Cabotegravir has the potential to play a primary role in the treatment and prevention of HIV infection. "
3.	Acquired Immunodeficiency Syndrome (AIDS) 01/05/2023 - "The first, sensitive, and rapid chiral method was developed for enatioseperations and determination of cabotegravir and its enantiomeric impurities by using HPLC and LC-MS. Cabotegravir is an antiretroviral medication used for the treatment of HIV/AIDS approved by the food and drugs administration (FDA) in the year 2021. " 01/01/2023 - "AIDS deaths are predicted to be averted with cabotegravir-PrEP introduction in 99% of setting-scenarios. " 01/01/2021 - "Long-Acting Cabotegravir for HIV/AIDS Prophylaxis." 01/01/2023 - "Despite leading to increases in integrase-inhibitor drug resistance, cabotegravir-PrEP introduction is likely to reduce AIDS deaths in addition to HIV incidence. " 08/01/2021 - "The approval of the novel long-acting HIV injection; Cabenuva®- Cabotegravir and Rilpivirine injectable formulation) and the recent call by the World Health Organization for promoting community-based ART management, underscore the remarkable progress towards meeting the Joint United Nations Programme on HIV/AIDS (UNAIDS) 95-95-95 targets by 2030. "
4.	Viremia 01/14/2015 - "All animals received a high-dose challenge of SHIV162P3 at week 1. No infection was detected in GSK744 LA-treated rhesus macaques, whereas viremia was detected 1 to 2 weeks after SHIV challenge in all control animals. " 01/01/2023 - "Transient Viremia in Young Adults With HIV After the Switch to Long-Acting Cabotegravir and Rilpivirine: Considerations for Dosing Schedule and Monitoring." 01/01/2021 - "Phase 3 data support the efficacy of nanoformulated injectable cabotegravir and rilpivirine for HIV treatment in patients with undetectable viremia, but we have yet to learn how this strategy may benefit those with medication adherence challenges. " 10/12/2023 - "Predictors of virologic failure in those receiving long acting injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) have been evaluated, however factors associated with low-level viremia, including blips and persistent low-level viremia (pLLV) are not well described. " 10/12/2023 - "Predictors of post-switch viremia in people with HIV on injectable cabotegravir/rilpivirine."
5.	Injection Site Reaction 10/21/2022 - "Injection-site reactions were common in clinical trials of cabotegravir and occurred in up to 81% of trial participants. " 01/01/2019 - " are awaiting the release of cabotegravir (CAB), which could represent a good option for patients struggling with adherence, despite injection site reactions.Pharmacogenetics" 01/01/2017 - "Despite high incidence of transient, mild-to-moderate injection-site reactions, long-acting cabotegravir was well tolerated with an acceptable safety profile. " 01/01/2022 - "Adverse event rates were similar across both groups, apart from injection site reactions, which were more frequent in the cabotegravir group than in the TDF-FTC group (577 [38·0%] of 1519 vs 162 [10·7%] of 1516]) but did not result in injection discontinuation. " 12/01/2021 - "Injection-site reactions were reported in 81.4% of the participants in the cabotegravir group and in 31.3% of those in the TDF-FTC group. "

Related Drugs and Biologics

1.	Rilpivirine (TMC-278)
2.	Tenofovir (Viread)
3.	Emtricitabine (Emtriva)
4.	Racivir
5.	dolutegravir
6.	bictegravir
7.	HIV Integrase
8.	Suspensions
9.	imidazole mustard (BIC)
10.	Raltegravir Potassium

Related Therapies and Procedures

1.	Injections
2.	Therapeutics
3.	Blood Transfusion (Blood Transfusions)
4.	Art Therapy